Clinical Trial Update: Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 study is evaluating osimertinib plus stereotactic radiosurgery (SRS) versus osimertinib alone in patients with EGFR-positive non-small cell lung cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Non-small Cell Lung Cancer

Drugs mentioned

• Osimertinib (osimertinib)

Snippet

Sponsor: British Columbia Cancer Agency | Conditions: Lung Cancer Non-small Cell Stage IV, Brain Metastases | Phase 2 | Status: ACTIVE_NOT_RECRUITING